← Back to Search

Stress Reduction for Heart Disease

N/A
Recruiting
Led By Ahmed Tawakol, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged between 30-65 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a stress-reducing intervention can help reduce inflammation in atherosclerotic plaque in adults.

Who is the study for?
This trial is for adults aged 30-65 who feel stressed out or have a stress score over 5. It's not for those with lower stress levels.
What is being tested?
The study tests if an 8-week program to reduce stress can decrease inflammation in blood vessels, measured by a special heart scan using PET and FDG.
What are the potential side effects?
Since the intervention involves stress reduction techniques, side effects are minimal but may include discomfort during relaxation exercises or emotional distress.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 30 and 65 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in arterial inflammation by PET

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Stress ReductionExperimental Treatment1 Intervention
8 week stress reduction course
Group II: ControlActive Control1 Intervention
No intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stress Reduction
2019
Completed Phase 3
~350

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,790 Total Patients Enrolled
16 Trials studying Atherosclerosis
4,489 Patients Enrolled for Atherosclerosis
Ahmed Tawakol, MDPrincipal Investigator - MGH
Massachusetts General Hospital, Massachusetts General Physicians Organization Inc
Stanford University School Of Medicine (Medical School)
Brigham & Women'S Hospital (Residency)
2 Previous Clinical Trials
51 Total Patients Enrolled
1 Trials studying Atherosclerosis
35 Patients Enrolled for Atherosclerosis

Media Library

Stress Reduction Clinical Trial Eligibility Overview. Trial Name: NCT04496947 — N/A
Atherosclerosis Research Study Groups: Stress Reduction, Control
Atherosclerosis Clinical Trial 2023: Stress Reduction Highlights & Side Effects. Trial Name: NCT04496947 — N/A
Stress Reduction 2023 Treatment Timeline for Medical Study. Trial Name: NCT04496947 — N/A
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top